These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
703 related articles for article (PubMed ID: 14562125)
21. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts. Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432 [TBL] [Abstract][Full Text] [Related]
23. [Real-time PCR array for simultaneous detection of 37 kinds of fusion genes in leukemia]. Liu HX; Zhu P; Zhang Y; Wang HX; DU JW; Liu J; Gu JY; Ou Y Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(8):526-32. PubMed ID: 17459201 [TBL] [Abstract][Full Text] [Related]
24. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Willasch AM; Gruhn B; Coliva T; Kalinova M; Schneider G; Kreyenberg H; Steinbach D; Weber G; Hollink IH; Zwaan CM; Biondi A; van der Velden VH; Reinhardt D; Cazzaniga G; Bader P; Trka J; Leukemia; 2009 Aug; 23(8):1472-9. PubMed ID: 19322206 [TBL] [Abstract][Full Text] [Related]
27. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction]. Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019 [TBL] [Abstract][Full Text] [Related]
28. [Molecular responses in acute promyelocytic leukemia patients monitored by real-time quantitative RT-PCR]. Yao L; Chen ZX; Cen JN Ai Zheng; 2008 Feb; 27(2):214-7. PubMed ID: 18279625 [TBL] [Abstract][Full Text] [Related]
29. The significance of minimal residual disease in patients with t(15;17). Grimwade D Best Pract Res Clin Haematol; 2002 Mar; 15(1):137-58. PubMed ID: 11987921 [TBL] [Abstract][Full Text] [Related]
30. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436 [TBL] [Abstract][Full Text] [Related]
32. Multiplex RT-PCR assay for the detection of major fusion transcripts in Taiwanese children with B-lineage acute lymphoblastic leukemia. Liang DC; Shih LY; Yang CP; Hung IJ; Chen SH; Jaing TH; Liu HC; Chang WH Med Pediatr Oncol; 2002 Jul; 39(1):12-7. PubMed ID: 12116073 [TBL] [Abstract][Full Text] [Related]
33. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Brüggemann M; Gökbuget N; Kneba M Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491 [TBL] [Abstract][Full Text] [Related]
35. Development of a NanoString assay to detect leukemogenic fusion transcripts in acute myeloid leukemia. Hu D; Zhou W; Wang F; Shu SM; Fan LL; He J; Wang P; He YL; Du W; Zhang JH; Duan JX; Sun L; Zheng J; Li XQ; Li HY; Feng XL; Huang SA Int J Lab Hematol; 2016 Dec; 38(6):663-673. PubMed ID: 27460049 [TBL] [Abstract][Full Text] [Related]
36. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Müller MC; Hördt T; Paschka P; Merx K; La Rosée P; Hehlmann R; Hochhaus A Acta Haematol; 2004; 112(1-2):30-3. PubMed ID: 15179002 [TBL] [Abstract][Full Text] [Related]
37. Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases. Weisser M; Haferlach C; Haferlach T; Schnittger S Cancer Genet Cytogenet; 2007 Aug; 177(1):64-9. PubMed ID: 17693194 [TBL] [Abstract][Full Text] [Related]
38. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454 [TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease in acute myeloid leukaemia. Liu Yin JA Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920 [TBL] [Abstract][Full Text] [Related]
40. [Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results]. Balwierz W; Pietrzyk JJ; Wator G; Stozek K; Klekawka T; Kwiecińska K; Dłuzniewska A; Matysiak M; Malinowska I; Sikorska-Fic B; Balcerska A; Maciejka-Kapuścińska L; Sońta-Jakimczyk D; Tomaszewska R; Chybicka A; Krawczuk-Rybak M; Muszyńska-Rosłan K; Młynarski W; Stolarska M; Urasiński T; Kamieńska E; Sobol G; Wieczorek M; Karolczyk G; Wysocki M; Kołtan S; Kowalczyk JR; Wójcik B; Ksiazek T; Szewczyk K Przegl Lek; 2010; 67(6):371-4. PubMed ID: 21344764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]